Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Novel technique may cut cost of bronchitis vaccine production
Infectious bronchitis remains a major problem in the global poultry industry. Because
Researchers grow IBV cell cultures in the laboratory

New research led by The Pirbright Institute could result in low-cost infectious bronchitis vaccine (IBV) production.

In a study published in the Journal of Virology, researchers describe how they genetically modified an IBV strain so that it could be grown in cell cultures in the laboratory, rather than inside hen eggs.

It is hoped the technique could lower the cost of vaccine production and make the process more efficient.

“To find the genetic code that made the lab strain able to replicate in cell cultures, we scanned the gene that produces the spike protein—the protein which enables the virus to attach to and enter cells—and found a genetic sequence which was unique to that virus,” explained Dr Bickerton, leader of the Coronaviruses group at Pirbright.  

“We were able to cut this sequence out of the lab strain and replace it in the vaccine strain to see if this allowed the vaccine strain to replicate in cell cultures too.”

Interestingly, the team discovered the sequence which allows lab growth of IBV strains results in the change of only three amino acids in the spike protein.

Dr Bickerton adds: “We can now apply this modification to other IBV vaccine strains, which will help improve the speed and efficiency of IBV studies and can eventually be applied to vaccine production”.

Despite there being an array of vaccines in existence, infectious bronchitis remains a major problem in the global poultry industry. Because the majority of IBV strains do not grow in cell cultures, IBV vaccines are grown in hen's eggs -  a process that is cumbersome and expensive.

Researchers estimate that a 10 per reduction in IBV incidence could save the global poultry industry £654 million. Boosting the efficiency and speed of IBV vaccine production is, therefore, crucial to reducing economic losses and welfare problems in chickens.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.